Additional file 1

Additional Methods

Outcome definitions:

- Major adverse cardiovascular event: Cardiovascular death, recurrent myocardial infarction hospitalization, ischemic stroke hospitalization, or heart failure hospitalization
- Cardiovascular death: ICD-10 code I* as the underlying cause of death
- Recurrent myocardial infarction hospitalization: ICD-10 code I21* or I22* as the primary diagnosis in hospital admission
- Ischemic stroke hospitalization: ICD-10 code I63* as any diagnosis in hospital admission
- Heart failure hospitalization: ICD-10 code I50* as primary diagnosis in hospital admission




Figure S1. Study flow-chart.




Figure S2. Cumulative incidence of major adverse cardiovascular event (MACE) after myocardial infarction in patients with type 1 diabetes and in unmatched control patients without any type of diabetes. Dashed lines represent 95% confidence intervals.

	All patients		Matched patient	
Outcome event	T1DM	No DM	T1DM	No DM
MACE	754	18,955	683	427
Cardiovascular death	411	10,943	378	233
Recurrent myocardial infarction	361	14,350	327	185
Ischemic stroke	146	3,944	131	88
Heart failure hospitalization	279	6,088	257	143

Table S1. Number of outcome events during 12-year follow-up.

	Cumulative incidence		Univariable		Multivariable	
Outcome	Type 1	No	sHR (95%CI)	<i>P</i> -value	sHR (95%CI)	<i>P</i> -value
	Diabetes	Diabetes				
MACE	68.4%	45.3%	2.18 (2.02-2.35)	< 0.0001	2.22 (2.02-2.43)	< 0.0001
Cardiovascular death	40.4%	28.3%	1.83 (1.66-2.03)	< 0.0001	1.83 (1.66-2.03)	< 0.0001
Recurrent myocardial infarction	33.6%	16.8%	2.40 (2.16-2.67)	< 0.0001	2.13 (1.89-2.40)	< 0.0001
Ischemic stroke	13.5%	10.0%	1.65 (1.40-1.95)	< 0.0001	1.71 (1.43-2.04)	< 0.0001
Heart failure hospitalization	25.5%	14.8%	2.15 (1.90-2.42)	< 0.0001	2.28 (1.98-2.63)	< 0.0001

Table S2. Cumulative incidences of outcomes in the total study cohort during the 12-year follow-up. Results of unadjusted and multivariable adjusted Fine-Gray models (see methods for details). sHR = subdistribution hazard ratio.

Kerola et al. 2022 Additional file 1 Cardiovasc Diabetol

	Type 1 diabetes / No diabetes					
Follow-up	MACE	Competing	Censored	At risk		
(years)		event				
0	0 / 0	0 / 0	0 / 0	1401 / 1401		
2	423 / 236	53 / 41	170 / 209	755 / 915		
4	552 / 330	79 / 67	321 / 390	449 / 614		
6	617 / 373	93 / 78	415 / 529	276 / 421		
8	655 / 399	99 / 85	502 / 649	145 / 268		
10	672 / 414	103 / 93	543 / 756	83 / 138		
12	683 / 427	106 / 94	612 / 880	35 / 48		

Table S3. Number of major adverse cardiovascular events (MACE), competing events (non-cardiovascular death), censored patients, and patients at risk during follow-up of patients with type 1 diabetes and of matched control patients without any type of diabetes after myocardial infarction. Please refer to Figure 1.